Histone methylation is thought to be important for regulating antigen-driven T cell responses. However, little is known about the impact of modulating histone methylation on inflammatory T cell responses. We demonstrate that in vivo administration of the histone methylation inhibitor 3-deazaneplanocin A (DZNep) arrests ongoing graft-versushost disease (GVHD) in mice after allogeneic bone marrow transplantation (BMT). DZNep caused selective apoptosis in alloantigen-activated T cells mediating host tissue injury. This effect was associated with DZNep's ability to selectively reduce trimethylation of histone H3 lysine 27 (H3K27me3), deplete the histone methyltransferase Ezh2 specific to H3K27me3 and activate pro-apoptotic gene Bim repressed by Ezh2 in antigenic-activated T cells. In contrast, DZNep did not impact the survival of alloantigen-unresponsive T cells in vivo and naïve T cells stimulated by IL-2 or IL-7 in vitro. Importantly, inhibition of histone methylation by DZNep treatment in vivo preserved the anti-leukemia activity of donor T cells and did not impair the recovery of hematopoiesis and lymphocytes, leading to significantly improved survival of recipients after allogeneic BMT. Our findings indicate that modulation of histone methylation may have significant implications in the development of novel approaches to treat ongoing GVHD and other T cell-mediated inflammatory disorders in a broad context.
Abstract
Histone methylation is thought to be important for regulating antigen-driven T cell responses. However, little is known about the impact of modulating histone methylation on inflammatory T cell responses. We demonstrate that in vivo administration of the histone methylation inhibitor 3-deazaneplanocin A (DZNep) arrests ongoing graft-versushost disease (GVHD) in mice after allogeneic bone marrow transplantation (BMT).
DZNep caused selective apoptosis in alloantigen-activated T cells mediating host tissue injury. This effect was associated with DZNep's ability to selectively reduce trimethylation of histone H3 lysine 27 (H3K27me3), deplete the histone methyltransferase Ezh2 specific to H3K27me3 and activate pro-apoptotic gene Bim repressed by Ezh2 in antigenic-activated T cells. In contrast, DZNep did not impact the survival of alloantigen-unresponsive T cells in vivo and naïve T cells stimulated by IL-2 or IL-7 in vitro. Importantly, inhibition of histone methylation by DZNep treatment in vivo preserved the anti-leukemia activity of donor T cells and did not impair the recovery of hematopoiesis and lymphocytes, leading to significantly improved survival of recipients after allogeneic BMT. Our findings indicate that modulation of histone methylation may have significant implications in the development of novel approaches to treat ongoing GVHD and other T cell-mediated inflammatory disorders in a broad context.
Introduction
Pathogenic T cell responses can be detrimental to the host. For example, graft-versushost disease (GVHD) is a life-threatening complication after allogeneic bone marrow transplantation (BMT) 1-3 . GVHD is caused by donor T cells that attack normal tissues of the recipient 1-3 . Standard immunosuppressive therapy for GVHD lacks efficacy and impairs the anti-tumor activity 1, 2, 4 . New approaches are needed to control GVHD.
Epigenetic modifications are thought to be important for T cell immune responses 5, 6 .
These modifications include histone methylation, DNA methylation and histone acetylation [7] [8] [9] [10] . Histone methylation is the modification of certain amino acids of a histone by adding methyl groups [8] [9] [10] . Depending on the site and degree of methylation, histone methylation can be activating or repressive. For example, trimethylation of histone H3 at lysine 4 (H3K4me3), H3K36me3 and H3K79me3 are associated with transcriptional activation, whereas H3K9me3, H3K27me3 and H4K20me3 are related to gene repression 8, 9 . Recent studies reveal that histone methylation may play important roles in regulating the expression of genes associated with survival, proliferation and differentiation of antigen-activated T cells 11, 12 . Unlike histone methylation, DNA methylation results in global silencing of gene expression 10 , whereas histone acetylation is associated with a relaxing chromatin structure that facilitates transcription 10 . It has been demonstrated that the DNA methylation inhibitor 5-Aza-2-deoxycytidine and the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) may prevent GVHD in mice through a mechanism of modulating regulatory T cells For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From (Tregs) 13, 14 and antigen-presenting cells (APCs) [15] [16] [17] , respectively. However, global modifications of DNA and chromatin structures are found to be associated with toxicities and adverse effects 10 . Thus, novel epigenetic approaches capable of targeting a specific set of genes in alloreactive T cells are desirable for controlling GVHD while minimizing adverse effects.
3-Deazaneplanocin A (DZNep) possesses the potent ability to selectively inhibit some histone methylation, such as H3K27me3, H3K4me3 and H4K20me3 18, 19 . DZNep is an inhibitor of S-adenosyl-L-homocysteine (AdoHcy) hydrolase. AdoHcy hydrolase catalyzes the reversible hydrolysis of AdoHcy to adenosine and homocysteine 20, 21 . When this enzyme is inhibited, AdoHcy accumulates in cells, leading to inhibition of the histone methyltransferease (HMT) activity and the subsequent histone methylation inhibition 20 . DZNep acts through a different pathway than DNA methylation inhibitors and HDAC inhibitors 10, 18, 19 In this report, we demonstrate that inhibition of histone methylation by DZNep arrested ongoing GVHD in mouse models of human allogeneic BMT. Importantly, DZNep therapy preserved the anti-leukemia activity and had no impairment on the hematopoietic reconstitution, leading to significantly improved survival of mice after allogeneic BMT and leukemia. Our findings suggest that pharmacologic inhibition of histone methylation should be explored as a novel strategy for controlling established GVHD. Cell preparation and culture. T cell depleted bone marrow (TCD BM), CD4 + T and CD8 + T cells were prepared as described 25 . T cells and spleen cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen). B6-derived CD4 + or CD8 + T cells were stimulated with anti-CD3 and anti-CD28 Ab conjugated microbeads (Miltenyi Biotech) in the presence of IL-2 (5ng/ml).
Induction of GVHD and graft-versus-leukemia (GVL). Mice underwent BMT as
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From described 25 . The GVHD score and severity was assessed as described 27 . GVHD severity was also assessed by histopathological analysis 28 . In GVL experiments, the leukemic cells A20 (1x10 6 ) were administered on the day when transplantation was performed. In vivo bioluminescence was used to monitor leukemia growth by intraperitoneal injection of 4.5 mg Firefly D-Luciferin (Biosynth, Switzerland) and assessed using the IVIS 200 system (Xenogen).
Real-time reverse transcription polymerase chain reaction (RT-PCR).
Total RNA was extracted from sorted T cell subsets using TRIzol (Invitrogen Life Technologies, Carlsbad, CA). Real-time RT-PCR was performed using a SYBR green PCR mix (ABI Biosystem, CA) in the Realplex 2 Eppendorf Real-time PCR instrument (Eppendorf AG, Westbury, NY). Gene expression levels were calculated relative to the GAPDH gene.
Data were collected and quantitatively analyzed on a Realplex sequence detection system (Eppendorf AG). The primer sequences are listed in Supplemental Table 1 .
Ex vivo and in vivo cytotoxicity assays. CFSE-based ex vivo and in vivo cytotoxicity assays were as described 29 . Statistical analysis. Survival in different groups was compared by using the log-rank test.
Comparison of two means was analyzed by using the two-sided two-sample T-test. Of note, DZNep treatment had no effect on the number of host T cells that are known not to respond to infused donor cells (Supplemental Fig.2A ). Furthermore, DZNep treatment led to a reduction in frequency of FoxP3 + CD4 + Tregs (Supplemental Fig.2B ).
Thus, DZNep-mediated reduction of alloantigen-reactive T cells may not be associated
with Tregs, which is in sharp contrast to the impact of DNA methylation inhibitors 5-AzaC on FoxP3 + CD4 + Tregs 13, 14 .
To assess the impact of DZNep treatment on GVHD, we transplanted T cell depleted bone marrow (TCD BM) from donor C3H.SW mice (H-2 b ), with and without For personal use only. on November 16, 2017. by guest www.bloodjournal.org From CD44 lo CD8 + naïve T cells (T N ), into lethally irradiated B6 mice ( Fig.1A ). This is a major histocompatibility complex (MHC)-identical but minor histocompatibility antigen (miHA)-mismatched mouse model of GVHD. We reasoned that administration of DZNep from days 3 to 17 after transplantation would permit initial activation of donor T cells. To Fig.4 ). In vitro cytotoxic assays showed that donor T cells derived from DZNep-treated B6 recipients of C3H.SW CD8 + T cells retained the ability to kill MBL-2 leukemic cells ( Fig. 2E ). In vivo CTL assay further confirmed that DZNep-treatment did not impair the cytolytic activity of donor CD8 + T cells against host hematopoietic cells ( Fig. 2F ).
Taken altogether, these data suggest that increased apoptosis in alloreactive CD8 + effector T cells may play a predominant role in DZNep-mediated inhibition of ongoing GVHD. 
DZNep induces apoptosis in T cell receptor (TCR)-activated T cells in vitro.

Previous studies suggested that DZNep inhibits histone methylation and depletes
Ezh2, leading to selective cell death in cancer but not normal cells via a mechanism of activating genes associated with apoptosis 18,19,22 . We then tested the impact of DZNep T-bet and Eomes are two transcription factors important for effector differentiation of activated CD8 + T cells 33, 34 . DZNep treatment increased the expression of Tbx21 but had no effect on Eomes expression in these activated CD8 + T cells (Fig.4B ). This coincides with our observations that DZNep did not affect the generation of effector T cells in vivo (Supplemental Fig.4 ).
Interestingly, DZNep effectively reduced cellular Ezh2 in these activated CD8 + T cells ( Fig.4D ). This was accompanied with elevated expression of genes specifically repressed by Ezh2 (e.g., Adrb2, Cdh1, Dab2ip and Cnr1) [35] [36] [37] (Fig.4E) . These results Fig.6 ). There were also markedly reduced donor T cells in the spleen and lymph node of DZNep-treated recipients at day 10 after transplantation (Supplemental Fig.7A ), which was accompanied with increased annexin V + apoptotic donor CD4 + T cells (Supplemental Fig. 7B ). Intriguingly, DZNep treatment did not affect the frequency of donor CD4 + T cells that produced high levels of effector cytokines as compared to the To further test this possibility, we purified CD44 lo CD4 + T N from B6 mice and cultured in the presence of anti-CD3 Ab + anti-CD28 Ab. Five days after TCR/CD28 stimulation, these activated CD4 + T cells were cultured in the presence of various concentrations of DZNep. DZNep dose-dependently reduced the recovery of activated CD4 + T cells 3 days after re-culture ( Fig.6A) . Importantly, DZNep treatment for 24 hours induced 1.8-fold more annexin V + CD4 + T cells than control (Fig.6B) . In contrast, DZNep treatment of CD4 + T N that were cultured in the presence of IL-7 or IL-2 alone did not affect their survival (Fig.6C ). Like its effects on activated CD8 + T cells, DZNep treatment markedly reduced H3K27me3, H3K4me3 and H3K36me in activated CD4 + T cells ( Fig.6D ), increased the expression of Bim, Bak and Bax (Fig.6E ), reduced cellular Ezh2 ( Fig.6F ) and activated genes specifically repressed by Ezh2 (Fig.6G) . Notably, we observed that DZNep treatment failed to inhibit GVHD in BALB/c mice receiving allogeneic donor T cells lacking Bim (Bim -/-T cells), with all of them dying of the disease (Fig.6H) . Thus, DZNep-induced GVHD inhibition may be accounted for, at least in part, by upregulating T cell expression of apoptotic gene Bim.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From DZNep preserves donor T cell-mediated GVL effects. To evaluate whether DZNep treatment retained GVL activity, we challenged BALB/c recipients with host-type A20 leukemia/lymphoma cells (H-2 d ), mimicking residual leukemia in patients receiving allogeneic BMT. We tracked luciferase-expressing A20 cells through bioluminescence imaging 26 . Mice transplanted with TCD BM and challenged with A20 cells died of leukemia ( Fig.7A-B) . In vivo administration of DZNep did not control leukemia growth in mice transplanted with TCD BM and challenged with A20 cells (Fig.7A-B ). No leukemia growth was observed in mice receiving donor TCD BM + CD4 + T cells, indicating potent GVL effect. However, all these mice succumbed to GVHD within 40 days after transplantation ( Fig.7B-D) . In contrast, treatment of mice receiving TCD BM + CD4 + T cells + A20 cells with DZNep from day 0 to day 27 after transplantation controlled leukemia without GVHD (Fig.7C) . As a result, more than 80% of DZNeptreated CD4 + T cell recipients survived free of leukemia ( Fig.7B-C) .
We further assessed the effect of delayed DZNep treatment on controlling leukemia and GVHD in BALB/c recipients challenged with A20 cells. Twelve doses of DZNep were given to mice receiving TCD BM + CD4 + T cells + A20 cells 7 to 29 days after transplantation. These DZNep-treated T cell recipients challenged with A20 cells completely eliminated leukemic cells by day 14 after transplantation and showed inhibition of GVHD (Fig.7B) . Consequently, approximately 80% of these recipients survived without leukemia and severe GVHD (Fig.7B, D) . In a separate experiment, we observed that donor T cells recovered from DZNep-treated T cell recipients had a similar cytolytic activity against A20 cells to that from controls (Fig.7E ). Taken altogether, these For personal use only. on November 16, 2017. by guest www.bloodjournal.org From data suggest that DZNep treatment can control CD4 + T cell-mediated GVHD while preserving beneficial GVL, leading to significantly improved survival of allogeneic BMT recipients.
We then used a second mouse model of allogeneic BMT and leukemia to validate these observations. Lethally irradiated BDF1 mice received parent B6 TCD BM, with or without CD4 + plus CD8 + T cells, were challenged with or without P815 leukemic cells (Supplemental Fig.8A ). We found that twelve doses of DZNep treatment from 7 to 29 days after transplantation reduced GVHD in BDF1 mice receiving donor T cells, with all of them surviving after transplantation (Supplemental Fig.8B) . In contrast, about 90% of control mice receiving donor T cells died from GVHD (Supplemental Fig.8B ). In this To further examine the effect of DZNep on T cells activated by specific antigens, we isolated TCR transgenic CD4 + and CD8 + T cells from OT-II mice and Pmel-1 mice 38 , and stimulated them in vitro with syngeneic DCs pulsed with different concentrations of the specific peptide OT-II and gp100, respectively. Three days later, DZNep was added into the cultures for additional 24 hours. We observed that DZNep only caused the reduction of T cells activated by high concentration of specific peptide, but not those stimulated with low concentration of peptide or without peptide (Supplemental Fig. 9C ). Thus, the activation status may differentiate the apoptotic effect of histone methylation inhibition on T cells. Table 2 ). As compared to untreated controls, mice treated with DZNep had a marginal reduction of lineage-negative (Lin -) Sca-1 + C-kit + hematopoietic stem/progenitor cells (LSK cells) without statistical significance (Supplemental Fig.10B ). Furthermore, DZNep did not impede the reconstitution of intestinal mucosa by rapidly proliferating enterocytes in these mice (data not shown).
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Discussion
To date, strategies to treat ongoing GVHD have been limited 2 . Many studies have demonstrated that continual generation of pathogenic host-reactive effector T cells is associated with the persistence and progression of GVHD 39, 40 . Thus, new strategies should target these host-reactive effector T cells. We found that DZNep inhibition of The mechanism that DZNep controls GVHD may differ from that mediated by either DNA methylation inhibitors 47, 48 or HDAC inhibitors 15, 17, 44 . For example, treatment with the DNA methylation inhibitor 5-AzaC led to upregulation of FoxP3, increased expansion of Tregs and amelioration of GVHD in mice 13, 14 , whereas in vivo administration of the pan HDAC inhibitor SAHA prevented the production of GVHD by modulating APC functions 15, 17, 44 . However, whether 5-AzaC and SAHA can control ongoing GVHD has not been reported 15, 17, 44 . In contrast, we found that DZNep resulted in a decrease in both frequency and number of FoxP3 + CD4 + Tregs during GVH reaction in allogeneic recipients. The major effect of DZNep-mediated inhibition of histone methylation was the selective induction of apoptosis in activated T cells. In addition, DZNep did not affect histone acetylation, which differs from SAHA's effect 15, 17, 44 . Thus, modulation of histone methylation may represent a novel and effective strategy to control ongoing GVHD. 
Several lines of evidence indicate that
GVHD induced by donor T cells lacking Bim. Most importantly, it has been shown that
Bim is a target gene specifically repressed by Ezh2. In agreement with previous studies of others 18, 19, 22, 45 , we found that DZNep depleted Ezh2 protein, reduce Ezh2-catalyzed H3K27me3 and activate genes repressed by Ezh2, which was accompanied with increased expression of Bim. In a separate study we have recently shown that alloreactive For personal use only. on November 16, 2017. by guest www.bloodjournal.org From CD8 + effector T cells increased the expression of Ezh2 24 . Reducing Ezh2 by small interference RNA selectively inhibited the proliferation of T cells stimulated with allogeneic APCs but not by IL-7 in vitro 24 . Therefore, it is highly likely that H3K27me3 and its catalyzing enzyme Ezh2 may account for DZNep-mediated effects on alloreactive effector T cells. Future studies will use genetic approaches to investigate the precise role of Ezh2 in T cell responses and the selectivity of DZNep's effect on Ezh2.
Many studies have demonstrated that alloreactive effector T cells mediating GVHD are also important for GVL activity, although not completely overlapping 1,46 . Therefore, inhibition of GVHD without impairing GVL effect has proven to be a difficult task 1 . We found that allogeneic DCs rather than leukemic cells activated allogeneic T cells to become effector T cells. DZNep treatment resulted in a reduction but not complete depletion of alloreactive effector T cells. These residual alloreactive T cells were sufficient to eliminating leukemic cells but not causing GVHD. Thus, it appears that the strength of GVH reaction required for controlling leukemia could be lower than that mediating GVHD. This is supported by our recent observations and others that eradication of leukemic cells after allogeneic BMT could be mediated by a lower threshold of allo-reactivity than induction of severe GVHD 29,47 . On the other hand, we found that in vivo administration of DZNep did not impair the induction of effector T cells during GVH reaction and the survival of T cells stimulated by cytokines. Since the expression of genes in DZNep-treated cells could return to the original levels within 24 hours after removal of the inhibitor 18 , and since the time-dependent disappearance of DZNep occurred between 30 minutes and 24 hours after in vivo administration 48 , it is possible that the treatment scheme of DZNep in mice every other day may allow surviving donor T cells to be reactivated to become effector T cells. This could be another explanation that the administration of DZNep at an interval of at least 48 hours in this study did not impair the induction of alloreactive effector T cells and their-mediated GVL activity. These data suggest that the potency of DZNep in regulating inflammatory T cell responses could also be adjusted based on the time intervals of administering the inhibitor.
A major concern with pharmacologic inhibition of histone methylation is its potential effects on the recovery of hematopoiesis and thymopoiesis after allogeneic BMT. We found that systemic administration of DZNep did not impair the engraftment For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
